Cullinan Oncology Q4 EPS $(0.54) Beats $(0.96) Estimate; Cash And Investments Of $468.3M As Of December 31, 2023 Continues To Provide Runway Into The Second Half Of 2026
Cullinan Oncology Q4 EPS $(0.54) Beats $(0.96) Estimate; Cash And Investments Of $468.3M As Of December 31, 2023 Continues To Provide Runway Into The Second Half Of 2026
Cullinan Oncology第四季度每股收益美元（0.54美元）超过预期（0.96美元）；截至2023年12月31日，4.683亿美元的现金和投资继续为2026年下半年提供资金支持
Cullinan Oncology (NASDAQ:CGEM) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.96) by 43.75 percent. This is a 40.66 percent increase over losses of $(0.91) per share from the same period last year.
库里南肿瘤学（纳斯达克股票代码：CGEM）公布的季度亏损为每股0.54美元（0.54美元），比分析师普遍预期的0.96美元（0.96美元）高出43.75％。与去年同期每股亏损0.91美元（0.91美元）相比，增长了40.66％。